Breathe Well Live Well
|
Vectura Inks Asthma/COPD License Agreement with Janssen
Genetic Engineering & Biotechnology News Vectura, a respiratory product development company, has entered a license agreement with Janssen Biotech to exclusively develop anti-inflammatory therapies for the treatment of asthma/COPD. The collaboration will initially focus on the development of a … |
View full post on asthma – Google News
|
Dynavax & AstraZeneca Alter Agreement for Asthma Product
Yahoo News As per the agreement, AstraZeneca will now provide full funding while Dynavax will conduct a phase IIa safety and efficacy trial on pipeline candidate AZD1419 in asthma patients. Dynavax plans to initiate the study in the first half of 2015. The … |
View full post on asthma – Google News
|
BRIEF-Vectura says in US collaboration agreement for VR506 asthma therapy
Reuters Announces a further US collaboration agreement with a leading international pharmaceutical company for VR506 asthma therapy. * Vectura's partner will be responsible for commercialisation and manufacture of product together with clinical development … |
View full post on asthma – Google News
|
Aerocrine: Aerocrine signs distribution agreement with third largest chinese …
The Herald | HeraldOnline.com The agreement, effective as of September 24, 2012, gives SPH exclusive rights for import and non-exclusive rights for distribution of Aerocrine's instrument NIOX MINO® and test kits, used for diagnosing and monitoring patients with asthma, on the … |
View full post on asthma – Google News
|
MediciNova Enters Into a $20 Million Common Stock Purchase Agreement With …
NASDAQ MediciNova will use the net proceeds from any sales of its stock to advance MediciNova's development activities for its lead programs, MN-221 (bedoradrine sulfate) in development for the treatment of acute asthma and chronic obstructive pulmonary … |
View full post on asthma – Google News
|
AstraZeneca And Rigel Sign Worldwide License Agreement For A …
MarketWatch (press release) "R256 emerged from Rigel's comprehensive study of chronic and severe asthma and lung inflammation. With AstraZeneca as our development partner, severely … |
View full post on asthma – Google News
 Proactive Investors USA & Canada |
AstraZeneca, Dynavax amend agreement to accelerate development of asthma drug
Proactive Investors USA & Canada AstraZeneca (NYSE:AZN) and Dynavax Technologies (NASDAQ:DVAX) announced Wednesday they have amended their collaboration agreement so as to accelerate the development of AZD1419, intended for the treatment of asthma. Under the terms of the agreement, … Dynavax and AstraZeneca to Advance TLR-9 Agonist Into Clinic for Asthma Dynavax gets $3M in reworked asthma deal with AstraZeneca |
View full post on asthma – Google News
|
Kos Pharmaceuticals and SkyePharma terminate license agreement for flutiform
Trading Markets (press release) Flutiform is used for adult and adolescent asthma. Under the terms of the agreement, Kos has the right to perform further clinical development for … Abbott, Skyepharma Part Ways On Asthma Drug Flutiform |
View full post on asthma – Google News
|
Nanotech Industries International Inc. Enters Into Definitive Agreement With …
MarketWatch (press release) In smaller amounts, isocyanates can also sensitize workers, making them subject to severe asthma attacks if they are exposed again. Death from severe asthma … |
View full post on asthma – Google News